| Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models H Kim, H Xu, E George, D Hallberg, S Kumar, V Jagannathan, ... Nature communications 11 (1), 3726, 2020 | 211 | 2020 |
| Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2α Q Wang, Z He, M Huang, T Liu, Y Wang, H Xu, H Duan, P Ma, L Zhang, ... Nature communications 9 (1), 559, 2018 | 195 | 2018 |
| PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma T Liu, W Ma, H Xu, M Huang, D Zhang, Z He, L Zhang, S Brem, ... Nature communications 9 (1), 3439, 2018 | 113 | 2018 |
| Circulating glioma cells exhibit stem cell-like properties T Liu, H Xu, M Huang, W Ma, D Saxena, RA Lustig, M Alonso-Basanta, ... Cancer research 78 (23), 6632-6642, 2018 | 100 | 2018 |
| The traditional Chinese medicine baicalein potently inhibits gastric cancer cells HX Jiasheng Mu, Tianrun Liu, Lin Jiang, Xiangsong Wu, Yang Cao, Maolan Li ... Journal of Cancer 7 (4), 453-61, 2016 | 95 | 2016 |
| Thioridazine, an antipsychotic drug, elicits potent antitumor effects in gastric cancer J Mu, H Xu, Y Yang, W Huang, J Xiao, M Li, Z Tan, Q Ding, L Zhang, J Lu, ... Oncology reports 31 (5), 2107-2114, 2014 | 71 | 2014 |
| Lithium down-regulates histone deacetylase 1 (HDAC1) and induces degradation of mutant huntingtin S Wu, SD Zheng, HL Huang, LC Yan, XF Yin, HN Xu, KJ Zhang, JH Gui, ... Journal of Biological Chemistry 288 (49), 35500-35510, 2013 | 58 | 2013 |
| Temporal DNA-PK activation drives genomic instability and therapy resistance in glioma stem cells Y Wang, H Xu, T Liu, M Huang, PP Butter, C Li, L Zhang, GD Kao, Y Gong, ... JCI insight 3 (3), 2018 | 54 | 2018 |
| Treatment and prognosis of anaplastic thyroid carcinoma: a clinical study of 50 cases TR Liu, ZW Xiao, HN Xu, Z Long, FQ Wei, SM Zhuang, XM Sun, LE Xie, ... PLoS One 11 (10), e0164840, 2016 | 51 | 2016 |
| Targeting lung cancer stem-like cells with TRAIL gene armed oncolytic adenovirus CL Yang Y, Xu H, Huang W, Ding M, Xiao J, Yang D, Li H, Liu XY J Cell Mol Med 19 (5), 915-23, 2015 | 51 | 2015 |
| Dopamine receptor D2 is correlated with gastric cancer prognosis HX Jiasheng Mu, Weidan Huang, Zhujun Tan, Maolan Li, Lin Zhang, Qichen Ding ... Oncology Letters, 2017 | 50 | 2017 |
| An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer SB Gitto, H Kim, S Rafail, DK Omran, S Medvedev, Y Kinose, ... Gynecologic Oncology 156 (1), 222-232, 2020 | 41 | 2020 |
| Thioridazine has potent antitumor effects on lung cancer stem‑like cells J SHEN, B MA, X ZHANG, X SUN, J HAN, Y WANG, L CHU, H XU, ... Oncology Letters, 2017 | 41 | 2017 |
| Altered β1,6‐GlcNAc branched N‐glycans impair TGF‐β‐mediated Epithelial‐to‐Mesenchymal Transition through Smad signalling pathway in human lung cancer N Li, H Xu, K Fan, X Liu, J Qi, C Zhao, P Yin, L Wang, Z Li, X Zha Journal of cellular and molecular medicine 18 (10), 1975-1991, 2014 | 41 | 2014 |
| HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy HN Xu, WD Huang, Y Cai, M Ding, JF Gu, N Wei, LY Sun, X Cao, HG Li, ... Molecular cancer 10, 1-14, 2011 | 38 | 2011 |
| CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models H Xu, E George, Y Kinose, H Kim, JB Shah, JD Peake, B Ferman, ... Cell Reports Medicine 2 (9), 2021 | 37 | 2021 |
| RGD-modifided oncolytic adenovirus exhibited potent cytotoxic effect on CAR-negative bladder cancer-initiating cells Y Yang, H Xu, J Shen, S Wu, J Xiao, Y Xu, XY Liu, L Chu Cell death & disease 6 (5), e1760-e1760, 2015 | 35 | 2015 |
| Prostate cancer-specific and potent antitumor effect of a DD3-controlled oncolytic virus harboring the PTEN gene M Ding, X Cao, H Xu, J Fan, H Huang, D Yang, Y Li, J Wang, R Li, XY Liu PLoS One 7 (4), e35153, 2012 | 32 | 2012 |
| Acetylcholinesterase overexpression mediated by oncolytic adenovirus exhibited potent anti-tumor effect H Xu, Z Shen, J Xiao, Y Yang, W Huang, Z Zhou, J Shen, Y Zhu, XY Liu, ... BMC cancer 14, 1-11, 2014 | 30 | 2014 |
| A Potent In Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon KJ Zhang, XF Yin, YQ Yang, HL Li, YN Xu, LY Chen, XJ Liu, SJ Yuan, ... Clinical Cancer Research 23 (8), 2038-2049, 2017 | 26 | 2017 |
